Share on StockTwits
 

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by Zacks to a “neutral” rating in a research report issued on Friday, AR Network reports. They currently have a $23.90 price target on the stock. Zacks‘ target price suggests a potential upside of 4.92% from the stock’s previous close.

A number of other analysts have also recently weighed in on ANIP. Analysts at Oppenheimer initiated coverage on shares of ANI Pharmaceuticals in a research note to investors on Wednesday. They set an “outperform” rating and a $29.00 price target on the stock. Analysts at Roth Capital initiated coverage on shares of ANI Pharmaceuticals in a research note to investors on Tuesday, January 7th. They set a “buy” rating and a $27.00 price target on the stock.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded down 0.79% on Friday, hitting $22.60. 110,399 shares of the company’s stock traded hands. ANI Pharmaceuticals has a 1-year low of $4.80 and a 1-year high of $25.75. The stock has a 50-day moving average of $18.92 and a 200-day moving average of $11.50. The company’s market cap is $214.2 million.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings data on Thursday, November 7th. The company reported $0.16 earnings per share (EPS) for the quarter.

ANI Pharmaceuticals, Inc, formerly BioSante Pharmaceuticals, Inc, is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism.

To view Zacks’ full report, visit www.zacks.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.